IBRX vs MKC · rev $113.3M vs P/E 8.4, $13.56B cap
Immunitybio Inc (IBRX) versus McCormick & Company Incorporated (MKC) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
McCormick & Company Incorporated (MKC) is a packaged foods company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
MKC does not have a complete income-statement cache yet.
IBRX currently screens at market cap $7.88B. MKC currently screens at market cap $13.56B and trailing P/E 8.4.
Not investment advice. Open the IBRX and MKC stock pages for the full models.
Not investment advice.